<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098917</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000396774</org_study_id>
    <secondary_id>UCLA-0406031-01</secondary_id>
    <secondary_id>NCI-6766</secondary_id>
    <nct_id>NCT00098917</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Clinical Trial of Mature Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells for the Treatment of Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body&#xD;
      build an effective immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating patients who are undergoing surgery for stage IB, stage II, or stage IIIA non-small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of adjuvant autologous dendritic cells loaded with&#xD;
           irradiated autologous tumor cells in patients with stage IB-IIIA non-small cell lung&#xD;
           cancer undergoing resection.&#xD;
&#xD;
        -  Determine the safety and tolerability of this vaccine in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the feasibility of this vaccine in these patients.&#xD;
&#xD;
        -  Determine vaccine-specific and antitumor immunity in patients treated with this vaccine.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients undergo leukaphersis to isolate peripheral blood mononuclear cells (PBMC). PBMC are&#xD;
      expanded ex vivo to generate monocyte-derived dendritic cells (DC). Autologous tumor cells&#xD;
      are harvested and purified at the time of surgical resection. DC are then loaded with&#xD;
      irradiated autologous tumor cells.&#xD;
&#xD;
      Within 4-8 weeks after surgical resection, patients receive autologous DC loaded with&#xD;
      irradiated autologous tumor cells intradermally on approximately days 1, 30, and 60 in the&#xD;
      absence of unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6-9 patients receive escalating doses of vaccine until the maximum tolerated dose&#xD;
      (MTD) is determined. If 2 of 9 patients in the first cohort experience dose-limiting&#xD;
      toxicity, that dose level is considered the MTD.&#xD;
&#xD;
      Patients are followed at approximately 1 and 4 months, and then every 6 months for 4 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-15 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>15</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumor cell derivative vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vaccine therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of non-small cell lung cancer&#xD;
&#xD;
               -  Clinical stage IB-IIIA disease&#xD;
&#xD;
          -  Candidate for surgical resection as primary treatment for tumor&#xD;
&#xD;
               -  Surgically resectable tumor ≥ 2.0 cm in diameter&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hematocrit ≥ 30%&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Hepatitis B surface antigen negative*&#xD;
&#xD;
          -  Hepatitis B core antigen negative*&#xD;
&#xD;
          -  Hepatitis C virus negative*&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal NOTE: *Screening performed only if liver&#xD;
             enzymes are elevated&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.2 mg/dL&#xD;
&#xD;
          -  BUN ≤ 40 mg/dL&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 &gt; 2.0 L (pre-resection) OR&#xD;
&#xD;
          -  Predicted post-resection FEV_1 &gt; 1.0 L&#xD;
&#xD;
          -  No more than 2 chronic obstructive pulmonary disease exacerbations requiring &gt; 2 weeks&#xD;
             of oral steroids and/or hospitalization within the past year&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  Purified protein derivative (PPD) skin test negative&#xD;
&#xD;
          -  HIV-1 and HIV-2 negative&#xD;
&#xD;
          -  No acute infection, including any acute viral, bacterial, or fungal infection&#xD;
             requiring specific therapy within the past 7 days&#xD;
&#xD;
          -  No allergy to study agents&#xD;
&#xD;
          -  No known autoimmune or collagen vascular disorder&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No underlying condition that would preclude study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent anti-tumor necrosis factor agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Standard adjuvant chemotherapy for lung cancer allowed provided therapy is completed ≥&#xD;
             30 days before administration of the first study vaccine&#xD;
&#xD;
          -  No concurrent cyclophosphamide&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent high-dose corticosteroids (e.g., &gt; 10 mg of prednisone)&#xD;
&#xD;
          -  Concurrent corticosteroids for minor breathing exacerbations allowed provided patient&#xD;
             receives ≤ 2 short courses (≤ 10 days per course) within a 45-day period&#xD;
&#xD;
          -  No concurrent corticosteroids within 48 hours before or after study vaccine&#xD;
             administration&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Standard adjuvant radiotherapy for lung cancer allowed provided therapy is completed ≥&#xD;
             30 days before administration of the first study vaccine&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent antihistamines within 48 hours before or after study vaccine&#xD;
             administration&#xD;
&#xD;
          -  No concurrent cimetidine or other H2 blockers within 48 hours before or after study&#xD;
             vaccine administration&#xD;
&#xD;
          -  Concurrent antibiotics for minor infection allowed provided patient receives ≤ 2 short&#xD;
             courses (≤ 10 days per course) within a 45-day period&#xD;
&#xD;
          -  No concurrent cyclosporine&#xD;
&#xD;
          -  No concurrent azathioprine&#xD;
&#xD;
          -  No other concurrent drugs known to significantly alter immune function&#xD;
&#xD;
          -  No concurrent cytotoxic therapy&#xD;
&#xD;
          -  No concurrent participation in another clinical trial involving experimental therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D. Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <last_update_submitted>January 24, 2008</last_update_submitted>
  <last_update_submitted_qc>January 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2008</last_update_posted>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

